Skip to main content
. 2020 Nov 20;12(24):25189–25206. doi: 10.18632/aging.104120

Figure 2.

Figure 2

Overexpression of wildtype SETD2 inhibits cancer cell growth in vitro. (A) Real-time qPCR showed the expression level of wildtype or catalytically dead version of SETD2 (F2478L mutant) in lung cancer cells H1650 and PC-9 and its overexpression. (B) Western blotting analyses of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpression in H1650 and PC-9 cells. Quantitative results were shown in the right panel. (C) Cell proliferation assays of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpressing H1650 and PC-9 cells. (D) Anchorage-independent growth assays of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpressing H1650 and PC-9 cells. Quantitative results were indicated in the right panel. (E) EDU staining of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpressed H1650 and PC-9 cells (×200). (F) Cell cycle analysis of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpressing H1650 and PC-9 cells. Proportion of cells in G0-G1 phase, S phase and G2-M phase was quantified. (G) Apoptosis analysis of wildtype or catalytically dead version of SETD2 (F2478L mutant) overexpressed H1650 and PC-9 cells by Annexin V/PI assay. *P<0.05, **P<0.01. Two-tailed Student’s t test.